Sanofi has secured a significant milestone in its development of venglustat, an innovative oral glucosylceramide synthase inhibitor (GCSi), with the…
Read More
Pfizer and Astellas Secure FDA Priority Review for Perioperative Padcev and Keytruda Combination in Muscle-Invasive Bladder Cancer
The United States Food and Drug Administration (FDA) has granted priority review to a supplemental biologics license application (sBLA) from…
Read More
FDA Proposes Permanent Authorization of Rare Pediatric Disease Priority Review Voucher Program to Foster Regulatory Stability
The United States Food and Drug Administration (FDA) is making a significant move to permanently authorize the rare pediatric disease…
Read More
The US Food and Drug Administration Convenes Public Hearing Amidst Scrutiny of Commissioner’s National Priority Voucher Program
The US Food and Drug Administration (FDA) is set to convene a significant public hearing on June 12, 2026, a…
Read MoreYOU MAY HAVE MISSED
